{"product_id":"roche-five-forces-analysis","title":"Roche  Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRoche faces strong buyer scrutiny, high supplier complexity, and intense rivalry driven by innovation and patent cliffs, while regulatory hurdles and moderate threats from new biologics shape its competitive landscape.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Roche’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche depends on scarce biologics and GMP-grade chemicals for oncology and immunology drugs; around 60–70% of these inputs come from a handful of certified suppliers, driving supplier leverage on pricing and lead times. In 2024 Roche reported supply-chain constraints that delayed some drug launches and raised COGS by ~2.1 percentage points, showing how niche dependency can affect margins and timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSwitching biologics suppliers triggers costly regulatory re-validation and batch comparability studies—often taking 12–24 months and costing $5–20M per product—so Roche rarely swaps partners, which strengthens incumbent suppliers.\u003c\/p\u003e\n\u003cp\u003eHigh switching costs push Roche toward multi-year contracts; in 2024 Roche reported over 60% of COGS tied to long-term supplier agreements, lowering price risk and securing capacity for high-margin biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Contract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe pharmaceutical industry now depends on a handful of large contract research organizations (CROs); the top 10 CROs captured about 68% of global clinical trial spending in 2024, per industry estimates. As CROs consolidate through deals like Thermo Fisher’s 2021 LabCorp buyout and Parexel’s private equity moves, their bargaining power versus Roche rises. Roche must negotiate sharply to secure access to specialized trial sites and biostatistics teams, or face 5–10% higher trial costs and longer timelines. This raises strategic risk to pipeline timing and R\u0026amp;D margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche reduces supplier bargaining power by diversifying sourcing across regions—in 2024 over 40% of procurement spend was split across Europe, North America, and Asia, lowering single-territory exposure.\u003c\/p\u003e\n\u003cp\u003eKeeping many vendors for non-critical parts creates redundancy so localized shocks (eg, 2023 Taiwan port delays) don’t halt production; this trims supplier leverage and shortens recovery time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 procurement: \u0026gt;40% geographically diversified\u003c\/li\u003e\n\u003cli\u003eMultiple vendors for non-critical components\u003c\/li\u003e\n\u003cli\u003eRedundancy limits single-supplier disruption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of Diagnostic Component Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche’s diagnostics division has vertically integrated reagent and hardware production, cutting supplier reliance and lowering supplier bargaining power; in 2024 Roche Diagnostics reported ~CHF 18.6 billion revenue, helping absorb upstream costs and protect margins.\u003c\/p\u003e\n\u003cp\u003eOwning key components ensures steady input supply for platforms like Cobas and Accu‑Chek, reducing supply disruption risk and improving gross margins versus peers who outsource.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Diagnostics revenue: CHF 18.6bn\u003c\/li\u003e\n\u003cli\u003eVertical integration lowers supplier dependence\u003c\/li\u003e\n\u003cli\u003eImproves input security for Cobas\/Accu‑Chek\u003c\/li\u003e\n\u003cli\u003eSupports margin protection versus outsourced peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche Faces Supplier Leverage Despite Diagnostics Scale and Diversified Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high power: 60–70% of GMP biologics from few certified vendors; 2024 supply issues raised COGS ~2.1ppt and delayed launches. Switching costs (12–24 months, $5–20M) keep Roche tied to incumbents; Diagnostics vertical integration (2024 revenue CHF 18.6bn) and \u0026gt;40% geographically diversified procurement cut supplier leverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP supplier concentration\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS impact (supply issues)\u003c\/td\u003e\n\u003ctd\u003e+2.1 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitch cost per product\u003c\/td\u003e\n\u003ctd\u003e$5–20M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003eCHF 18.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement geographic split\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Roche uncovering competitive pressures, supplier and buyer influence, threat of substitutes and new entrants, and strategic barriers protecting its market position—ideal for investor reports, strategy decks, and academic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces summary for Roche—quickly spot competitive threats and bargaining pressures to streamline strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Government Procurement and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational health systems and big insurers are Roche’s main buyers for high-cost drugs; in 2024 public payers accounted for roughly 60% of global pharma spending, giving them huge leverage.\u003c\/p\u003e\n\u003cp\u003eThese buyers use volume to extract steep discounts and outcome-based rebates—procurement contracts often cut list prices by 20–40% in EU markets in 2023–24.\u003c\/p\u003e\n\u003cp\u003eWith global healthcare spending growth slowing to ~3.8% in 2024 and median payer cost-effectiveness thresholds tightening, Roche faces rising demand to prove value per QALY and accept risk-sharing deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US, pharmacy benefit managers (PBMs) control formularies for ~70% of commercially insured lives, giving them power to exclude or place Roche drugs in high-cost tiers and sharply reduce volumes.\u003c\/p\u003e\n\u003cp\u003ePBM leverage forces Roche to offer steep rebates—industry median rebates hit ~30% in 2024—plus robust Phase III evidence to secure preferred placement.\u003c\/p\u003e\n\u003cp\u003eLoss of formulary access can cut peak sales by 40–60% for specific oncology and immunology therapies, so Roche must price competitively and show real-world outcomes to keep access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift Toward Value-Based Pricing Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe global move to value-based pricing—estimated at a 12% annual adoption rate in OECD markets by 2024—means payers increasingly reimburse for outcomes, not volume, directly boosting customer leverage over Roche’s oncology and rare-disease drugs; Roche must therefore tie prices to survival, response rates, or patient-reported outcomes. To support these contracts Roche needs major analytics spend—roughly $500–700m annually in real-world evidence and data platforms by 2025—to validate performance-linked pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Diagnostic Laboratory Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsolidation of diagnostic lab chains (eg, Labcorp, Quest Diagnostics) concentrates buying power: the top 5 US lab chains handle ~60% of outpatient tests, letting them push for 5–15% price concessions on instruments and high-volume reagents in 2024–25.\u003c\/p\u003e\n\u003cp\u003eRoche faces pressure to offer integrated, high-throughput platforms and service bundles; losing scale discounts risks volume shrinkage as chains negotiate multi-vendor tenders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 5 chains ≈60% outpatient test share\u003c\/li\u003e\n\u003cli\u003ePrice concessions commonly 5–15%\u003c\/li\u003e\n\u003cli\u003eDemand for integrated platforms up since 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Informed Decision Making\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups now guide treatment priorities; 68% of EU health tech coverage decisions in 2023 cited patient input, shifting demand toward patient-centered Roche offerings.\u003c\/p\u003e\n\u003cp\u003eThese groups influence policy and pricing—public campaigns helped secure higher reimbursement in 2022 oncology cases, changing Roche’s market-access tactics and launch sequencing.\u003c\/p\u003e\n\u003cp\u003eRoche must engage advocacy stakeholders to protect reputation and align R\u0026amp;D with needs; patient-led trials rose 22% globally in 2024, showing the trend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% EU coverage decisions cited patient input (2023)\u003c\/li\u003e\n\u003cli\u003eOncology reimbursement wins tied to advocacy (2022)\u003c\/li\u003e\n\u003cli\u003ePatient-led trials +22% globally (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs \u0026amp; labs squeeze Roche: 20–40% discounts, ~30% rebates; formulary loss cuts sales 40–60%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge public payers and PBMs wield strong leverage over Roche, extracting 20–40% discounts and ~30% rebates in 2024 and pushing outcome-based contracts as value thresholds tighten; loss of formulary access can cut peak sales 40–60%. Consolidated lab chains (top 5 ≈60% outpatient share) demand 5–15% concessions on instruments\/reagents, while patient advocacy now influences coverage (68% EU decisions in 2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer share of pharma spend (public)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical EU procurement discounts\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndustry median rebates (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary loss sales impact\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 5 US lab outpatient share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab price concessions\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU coverage decisions citing patients (2023)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eRoche  Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Roche Porter's Five Forces analysis you'll receive immediately after purchase—fully formatted, professionally written, and ready for download with no placeholders or mockups.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the complete, final document: the same deliverable will be available for instant access post-purchase and requires no further setup or customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746781933945,"sku":"roche-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/roche-five-forces-analysis.png?v=1772191815","url":"https:\/\/matrixbcg.com\/products\/roche-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}